February 24, 2022
Life Sciences
  • Sanofi and GSK said they plan to submit their COVID-19 vaccine for authorization to the FDA and the European Medicines Agency. Two doses of the vaccine had 100 percent efficacy against severe disease and hospitalization. Efficacy against any infection at all was 57.9 percent, which the companies said is “in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.” (Articles here, here, here, and here)